Top

Published in:

01-07-2015 | Original Article

High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression

Authors: Hasan Esen, Bahadır Feyzioglu, Fatih Erdi, Fatih Keskin, Bulent Kaya, Lutfi Saltuk Demir

Published in: Brain Tumor Pathology | Issue 3/2015

Abstract

Thioredoxin (Trx) is a redox active protein that regulates several physiological and biochemical functions, such as growth, apoptosis and cellular defense. The function of Trx itself is regulated by thioredoxin reductase (TrxR). This study was designed to determine the expression of TrxR1 in meningioma tissues of different World Health Organization grades (grade I–III). Meningioma tissues were extracted from the histopathological specimens of 29 patients. These samples included seven histologically normal meningeal tissues that served as a control group and 12 grade I, 12 grade II and 5 grade III meningioma samples. TrxR1 expression was evaluated using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunostaining. The proliferative and apoptotic indices of the specimens were investigated by Ki-67 immunostaining and TUNEL assay, respectively. TrxR1 expression, as assessed by qRT-PCR, increased significantly with meningioma grade (p < 0.001). The immunostaining intensity of TrxR1 increased significantly with meningioma grade (p < 0.001). Ki-67 index values increased significantly in accordance with grade progression (p < 0.001). The apoptotic index values were not significantly different in any group (p > 0.05). Trx system seems to be involved in the malignant progression of meningiomas. Further, large studies are required to elucidate the exact role of this system.

Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P (2005) Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114(2):249–256PubMedCrossRef

Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ (2000) Meningiomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 176–189

Haapasalo H, Kyläniemi M, Paunul N, Kinnula VL, Soini Y (2003) Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol 13(2):155–164PubMedCrossRef

Kemerdere R, Kacira T, Hanimoglu H, Kucur M, Tanriverdi T, Canbaz B (2013) Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme. J Neurol Surg A Cent Eur Neurosurg 74(4):234–238PubMedCrossRef

Yagublu V, Arthur JR, Babayeva SN, Nicol F, Post S, Keese M (2011) Expression of selenium-containing proteins in human colon carcinoma tissue. Anticancer Res 31(9):2693–2698PubMed

Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 4:6–13PubMedCrossRef

Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G (1996) Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16:3459–3466PubMed

Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, Kim JR (2002) Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22:3331–3335PubMed

Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL (2001) Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7:3087–3091PubMed

10.

Esen H, Erdi F, Kaya B, Feyzioglu B, Keskin F, Demir LS (2014) Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. J Neurooncol (Epub ahead of print). doi:10.1007/s11060-014-1661-5

11.

Järvelä S, Bragge H, Paunu N, Järvelä T, Paljärvi L, Kalimo H, Helén P, Kinnula V, Soini Y, Haapasalo H (2006) Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol 77:131–140PubMedCrossRef

12.

Ahmadi R, Urig S, Hartmann M, Helmke BM, Koncarevic S, Allenberger B, Kienhoefer C, Neher M, Steiner HH, Unterberg A, Herold-Mende C, Becker K (2006) Antiglioma activity of 2,2′:6′,2′′-terpyridineplatinum[II] complexes in a rat model-effects on cellular redox metabolism. Free Radic Biol Med 40:763–778PubMedCrossRef

13.

Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC (2007) Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69:831–838PubMedCrossRef

14.

Huang T, Jin X, He L, Zhang M, Wu J, Wang Y, Fang J (2013) Role of podocalyxin in astrocytoma: clinicopathological and in vitro evidence. Oncol Lett 6(5):1390–1396PubMedPubMedCentral

15.

Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73:936–942PubMedCrossRef

16.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

17.

Arnér ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16:420–426PubMedCrossRef

18.

Powis G, Kirkpatrick DL, Angulo M, Baker A (1998) Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 111–112:23–34PubMedCrossRef

19.

Söderberg A, Sahaf B, Rosén A (2000) Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res 60:2281–2289PubMed

20.

Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K (1995) Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55:4293–4296PubMed

Title: High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression
Authors: Hasan Esen
Bahadır Feyzioglu
Fatih Erdi
Fatih Keskin
Bulent Kaya
Lutfi Saltuk Demir
Publication date: 01-07-2015
Publisher: Springer Japan
Published in: Brain Tumor Pathology / Issue 3/2015
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-015-0212-x

2024 ASCO Annual Meeting

Springer Medicine

High thioredoxin reductase 1 expression in meningiomas undergoing malignant progression

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

TTF-1-positive oncocytic sellar tumor with follicle formation/ependymal differentiation: non-adenomatous tumor capable of two different interpretations as a pituicytoma or a spindle cell oncocytoma

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas

Familial schwannomatosis with a germline mutation of SMARCB1 in Japan

Applicable advances in the molecular pathology of glioblastoma

Involvement of epimutations in meningioma

The density of microvessels positive for Wilms’ tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas